258 related articles for article (PubMed ID: 16166190)
21. [The mental disorder and obsessive-compulsive spectrum disorders in childhood ].
Okada T
Seishin Shinkeigaku Zasshi; 2011; 113(10):992-8. PubMed ID: 22292193
[No Abstract] [Full Text] [Related]
22. Use of atypical neuroleptics in child and adolescent psychiatry.
Toren P; Laor N; Weizman A
J Clin Psychiatry; 1998 Dec; 59(12):644-56. PubMed ID: 9921698
[TBL] [Abstract][Full Text] [Related]
23. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
Dold M; Aigner M; Lanzenberger R; Kasper S
Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25939614
[TBL] [Abstract][Full Text] [Related]
24. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Williams K; Wheeler DM; Silove N; Hazell P
Cochrane Database Syst Rev; 2010 Aug; (8):CD004677. PubMed ID: 20687077
[TBL] [Abstract][Full Text] [Related]
25. Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study.
Martin A; Koenig K; Anderson GM; Scahill L
J Autism Dev Disord; 2003 Feb; 33(1):77-85. PubMed ID: 12708582
[TBL] [Abstract][Full Text] [Related]
26. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
27. Medications for adolescents and young adults with autism spectrum disorders: a systematic review.
Dove D; Warren Z; McPheeters ML; Taylor JL; Sathe NA; Veenstra-VanderWeele J
Pediatrics; 2012 Oct; 130(4):717-26. PubMed ID: 23008452
[TBL] [Abstract][Full Text] [Related]
28. Risperidone in pervasive developmental disorders.
Erickson CA; Stigler KA; Posey DJ; McDougle CJ
Expert Rev Neurother; 2005 Nov; 5(6):713-9. PubMed ID: 16274329
[TBL] [Abstract][Full Text] [Related]
29. Off-label second generation antipsychotics for impulse regulation disorders: a review.
Scheltema Beduin A; de Haan L
Psychopharmacol Bull; 2010; 43(3):45-81. PubMed ID: 21150846
[TBL] [Abstract][Full Text] [Related]
30. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA
PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122
[TBL] [Abstract][Full Text] [Related]
31. Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan.
Doyle CA; McDougle CJ
Dialogues Clin Neurosci; 2012 Sep; 14(3):263-79. PubMed ID: 23226952
[TBL] [Abstract][Full Text] [Related]
32. Pharmacotherapy of children and adolescents with pervasive developmental disorders.
Hanft A; Hendren RL
Essent Psychopharmacol; 2004; 6(1):12-24. PubMed ID: 15612651
[No Abstract] [Full Text] [Related]
33. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors.
McDougle CJ; Kresch LE; Posey DJ
J Autism Dev Disord; 2000 Oct; 30(5):427-35. PubMed ID: 11098879
[TBL] [Abstract][Full Text] [Related]
34. Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries.
Mishu MP; Uphoff E; Aslam F; Philip S; Wright J; Tirbhowan N; Ajjan RA; Al Azdi Z; Stubbs B; Churchill R; Siddiqi N
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013281. PubMed ID: 33591592
[TBL] [Abstract][Full Text] [Related]
35. The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials.
Hedges DW; Brown BL; Shwalb DA; Godfrey K; Larcher AM
J Psychopharmacol; 2007 Jan; 21(1):102-11. PubMed ID: 16714326
[TBL] [Abstract][Full Text] [Related]
36. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.
McDougle CJ; Stigler KA; Erickson CA; Posey DJ
J Clin Psychiatry; 2008; 69 Suppl 4():15-20. PubMed ID: 18533764
[TBL] [Abstract][Full Text] [Related]
37. [Pharmacological treatments in patients with pervasive developmental disorders: A review].
Béhérec L; Quilici G; Rosier A; Gerardin P; Campion D; Guillin O
Encephale; 2014 Apr; 40(2):188-96. PubMed ID: 24369879
[TBL] [Abstract][Full Text] [Related]
38. Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study.
Troost PW; Althaus M; Lahuis BE; Buitelaar JK; Minderaa RB; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):561-73. PubMed ID: 17069545
[TBL] [Abstract][Full Text] [Related]
39. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.
Lorenz RA; Jackson CW; Saitz M
Pharmacotherapy; 2010 Sep; 30(9):942-51. PubMed ID: 20795849
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
